Related Experiment Videos
New reference levels for CA125 in pre- and postmenopausal women
Nguyen1, Jacobson, Patino-Paul
1Cleveland Clinic Florida, Florida, Ft. Lauderdale, USA
Primary Care Update for Ob/Gyns
|June 6, 2000
Summary
This study establishes new, stratified reference ranges for CA125 (cancer antigen 125) levels in women based on menopausal and bleeding status. These refined ranges improve the accuracy of ovarian cancer screening by accounting for normal physiological variations.
Area of Science:
- Gynecologic Oncology
- Biomarker Research
- Clinical Chemistry
Background:
- CA125 (cancer antigen 125) is a glycoprotein utilized for ovarian cancer screening.
- The established normal upper limit for serum CA125 is 35 U/mL.
- CA125 levels can fluctuate with menopausal status and vaginal bleeding.
Purpose of the Study:
- To develop distinct reference ranges for serum CA125 in women across different physiological states.
- To enhance the specificity of ovarian cancer screening by considering normal variations in CA125.
Main Methods:
- Retrospective analysis of 1,407 patient serum CA125 levels.
- Exclusion of patients with known gynecologic cancers.
- Statistical comparison of CA125 means using Student t-test.
Main Results:
- Significant differences in mean CA125 were observed between premenopausal (19.3 U/mL) and postmenopausal (11.7 U/mL) women.
- Premenopausal CA125 levels differed significantly between menses (21.4 U/mL) and luteal phase (14.0 U/mL).
- Postmenopausal women with vaginal bleeding had higher CA125 (12.49 U/mL) than those without (9.62 U/mL).
Conclusions:
- Recommended upper CA125 limits for premenopausal women: 50 U/mL overall, 62 U/mL during menses, 51 U/mL proliferative phase, 32 U/mL luteal phase.
- Recommended upper CA125 limits for postmenopausal women: 35 U/mL with bleeding, 20 U/mL without bleeding.
- Stratified CA125 values can improve ovarian cancer screening specificity.
